Insulin Glulisine Administered Pre-meal Versus Post-meal in Adult Subjects With Type 2 Diabetes Mellitus Receiving Insulin Glargine as Basal Insulin

PHASE3CompletedINTERVENTIONAL
Enrollment

345

Participants

Timeline

Start Date

August 31, 2004

Study Completion Date

July 31, 2007

Conditions
Diabetes Mellitus, Type 2
Interventions
DRUG

insulin glulisine

PREMEAL ARM: Subjects randomized to this arm will receive Apidra administered three times per day 0-15 min before the three main meals; metformin (if applicable); and Lantus qd for 52 weeks.

DRUG

insulin glargine

POSTMEAL ARM: Subjects randomized to this arm will receive Apidra administered three times per day immediately after a meal (20 min after the start of a meal); metformin (if applicable); and Lantus qd for 52 weeks.

Trial Locations (1)

08807

Sanofi-aventis, Bridgewater

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Sanofi

INDUSTRY